{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T06:05:11Z","timestamp":1790057111242,"version":"4.0.1"},"reference-count":63,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T00:00:00Z","timestamp":1790035200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Pain Res."],"abstract":"<jats:sec>\n                    <jats:title>Background<\/jats:title>\n                    <jats:p>Chemotherapy-induced peripheral neuropathy (CIPN) is a common complication of neurotoxic chemotherapy, yet effective pharmacologic options for both prevention and treatment of established painful CIPN remain limited. Non-delta-9-tetrahydrocannabinol (THC) cannabinoids and related minor cannabinoids show antinociceptive effects in preclinical CIPN models, but their real-world clinical relevance remains unclear.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>We performed a retrospective secondary analysis of de-identified electronic health record (EHR) data using the TriNetX Research Network to examine whether documented cannabidiol\/cannabigerol (CBD\/CBG) exposure was associated with subsequent neuropathy-related diagnoses among adults receiving neurotoxic chemotherapy. Patients with neuropathy-related diagnoses on or before chemotherapy were excluded. Two Cox proportional hazards analyses were performed. The post-chemotherapy exposure analysis compared post-chemotherapy CBD\/CBG exposure with post-chemotherapy exposure to gabapentin, pregabalin, or duloxetine. The pre-chemotherapy exposure analysis compared patients with documented CBD\/CBG exposure within one year before chemotherapy to patients who had no documented CBD\/CBG exposure during that pre-chemotherapy window. The outcome was a composite neuropathy-related diagnosis 30\u2013365 days after the index event.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      In the adjusted post-chemotherapy exposure model, 83 CBD\/CBG-exposed patients were compared with 118,001 active-comparator patients. Post-chemotherapy CBD\/CBG exposure was associated with lower hazard of subsequent neuropathy-related diagnosis-code outcomes (Hazard ratio [HR]\u2009=\u20090.162, 95% confidence interval [CI]\u2009=\u20090.041\u20130.649,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.010). In the adjusted pre-chemotherapy exposure model, 162 CBD\/CBG-exposed patients were compared with 633,329 controls. Pre-chemotherapy CBD\/CBG exposure was not significantly associated with neuropathy-related diagnosis-code outcomes (HR\u2009=\u20090.859, 95% CI\u2009=\u20090.476\u20131.551,\n                      <jats:italic>p<\/jats:italic>\n                      \u2009=\u20090.614).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Conclusions<\/jats:title>\n                    <jats:p>Post-chemotherapy CBD\/CBG exposure was associated with lower observed hazard of neuropathy-related diagnosis-code outcomes, whereas pre-chemotherapy exposure was not significant. These exploratory findings require cautious interpretation because of sparse exposed-arm events, EHR exposure limitations, and potential competing-risk bias.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fpain.2026.1945720","type":"journal-article","created":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:40:43Z","timestamp":1790055643000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":0,"title":["Cannabidiol\/cannabigerol exposure and neuropathy-related outcomes after neurotoxic chemotherapy: a real-world cohort study"],"prefix":"10.3389","volume":"7","author":[{"given":"Nicholas M.","family":"Graziane","sequence":"first","affiliation":[{"name":"Departments of Anesthesiology and Perioperative Medicine and Neuroscience and Experimental Therapeutics, Penn State College of Medicine","place":["Hershey, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ajay","family":"Macherla","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Penn State College of Medicine","place":["Hershey, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Matthew","family":"Giampetro","sequence":"additional","affiliation":[{"name":"Department of Anesthesiology and Perioperative Medicine, Penn State College of Medicine","place":["Hershey, PA, United States"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,9,22]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"S1","DOI":"10.1097\/j.pain.0000000000001540","article-title":"Chemotherapy-induced peripheral neuropathy: where are we now?","volume":"160","author":"Colvin","year":"2019","journal-title":"Pain"},{"key":"B2","doi-asserted-by":"publisher","first-page":"47","DOI":"10.1007\/s11910-017-0757-7","article-title":"Update on chemotherapy-induced peripheral neuropathy","volume":"17","author":"Cioroiu","year":"2017","journal-title":"Curr Neurol Neurosci Rep"},{"key":"B3","doi-asserted-by":"publisher","first-page":"1451","DOI":"10.3390\/ijms20061451","article-title":"Mechanisms of chemotherapy-induced peripheral neuropathy","volume":"20","author":"Zaj\u0105czkowska","year":"2019","journal-title":"Int J Mol Sci"},{"key":"B4","doi-asserted-by":"publisher","first-page":"e00558","DOI":"10.1002\/brb3.558","article-title":"Chemotherapy-induced neuropathies-a growing problem for patients and health care providers","volume":"7","author":"Banach","year":"2017","journal-title":"Brain Behav"},{"key":"B5","doi-asserted-by":"publisher","first-page":"1227","DOI":"10.1007\/s11912-023-01449-7","article-title":"Chemotherapy-induced peripheral neuropathy: diagnosis, agents, general clinical presentation, and treatments","volume":"25","author":"Molinares","year":"2023","journal-title":"Curr Oncol Rep"},{"key":"B6","doi-asserted-by":"publisher","first-page":"3325","DOI":"10.1200\/JCO.20.01399","article-title":"Prevention and management of chemotherapy-induced peripheral neuropathy in survivors of adult cancers: aSCO guideline update","volume":"38","author":"Loprinzi","year":"2020","journal-title":"J Clin Oncol"},{"key":"B7","doi-asserted-by":"publisher","first-page":"Cd012182","DOI":"10.1002\/14651858.CD012182.pub2","article-title":"Cannabis-based medicines for chronic neuropathic pain in adults","volume":"2020","author":"M\u00fccke","year":"2020","journal-title":"Cochrane Database Syst Rev"},{"key":"B8","doi-asserted-by":"publisher","first-page":"1143","DOI":"10.7326\/M21-4520","article-title":"Cannabis-based products for chronic pain: a systematic review","volume":"175","author":"McDonagh","year":"2022","journal-title":"Ann Intern Med"},{"key":"B9","doi-asserted-by":"publisher","first-page":"1593","DOI":"10.1152\/physrev.00002.2016","article-title":"From phytocannabinoids to cannabinoid receptors and endocannabinoids: pleiotropic physiological and pathological roles through complex pharmacology","volume":"96","author":"Ligresti","year":"2016","journal-title":"Physiol Rev"},{"key":"B10","doi-asserted-by":"publisher","first-page":"75","DOI":"10.1016\/j.copsyc.2021.03.003","article-title":"Cannabis and driving ability","volume":"38","author":"Sevigny","year":"2021","journal-title":"Curr Opin Psychol"},{"key":"B11","doi-asserted-by":"publisher","first-page":"2324","DOI":"10.1007\/s13311-021-01127-1","article-title":"Cannabinoids: an effective treatment for chemotherapy-induced peripheral neurotoxicity?","volume":"18","author":"Cavaletti","year":"2021","journal-title":"Neurotherapeutics"},{"key":"B12","doi-asserted-by":"publisher","first-page":"969","DOI":"10.1007\/s40265-019-01132-x","article-title":"Cannabinoids: current and future options to treat chronic and chemotherapy-induced neuropathic pain","volume":"79","author":"Blanton","year":"2019","journal-title":"Drugs"},{"key":"B13","doi-asserted-by":"publisher","first-page":"166","DOI":"10.1016\/j.jpainsymman.2013.02.018","article-title":"A double-blind, placebo-controlled, crossover pilot trial with extension using an oral mucosal cannabinoid extract for treatment of chemotherapy-induced neuropathic pain","volume":"47","author":"Lynch","year":"2014","journal-title":"J Pain Symptom Manage"},{"key":"B14","doi-asserted-by":"publisher","first-page":"78","DOI":"10.1093\/jncimonographs\/lgab007","article-title":"Cannabinoids and cancer chemotherapy-associated adverse effects","volume":"2021","author":"Ward","year":"2021","journal-title":"J Natl Cancer Inst Monogr"},{"key":"B15","doi-asserted-by":"publisher","first-page":"1357","DOI":"10.1039\/C6NP00074F","article-title":"Phytocannabinoids: a unified critical inventory","volume":"33","author":"Hanu\u0161","year":"2016","journal-title":"Nat Prod Rep"},{"key":"B16","doi-asserted-by":"publisher","first-page":"1442","DOI":"10.3390\/ph16101442","article-title":"Chronic cannabigerol as an effective therapeutic for cisplatin-induced neuropathic pain","volume":"16","author":"Nachnani","year":"2023","journal-title":"Pharmaceuticals (Basel)"},{"key":"B17","doi-asserted-by":"publisher","first-page":"83","DOI":"10.3390\/biomedicines12010083","article-title":"Antinociceptive effects of cannabichromene (CBC) in mice: insights from von frey, tail-flick, formalin, and acetone tests","volume":"12","author":"Raup-Konsavage","year":"2023","journal-title":"Biomedicines"},{"key":"B18","doi-asserted-by":"publisher","first-page":"1950","DOI":"10.1002\/ejp.2016","article-title":"Cannabigerol (CBG) attenuates mechanical hypersensitivity elicited by chemotherapy-induced peripheral neuropathy","volume":"26","author":"Sepulveda","year":"2022","journal-title":"Eur J Pain"},{"key":"B19","doi-asserted-by":"publisher","DOI":"10.1111\/bph.70281","article-title":"Cannabigerol reverses mechanical allodynia through \u03b1(2A)-adrenergic modulation of thalamocortical signaling in chemotherapy-induced neuropathy","author":"Wade","year":"2025","journal-title":"Br J Pharmacol"},{"key":"B20","doi-asserted-by":"publisher","first-page":"636","DOI":"10.1111\/bph.12439","article-title":"Cannabidiol inhibits paclitaxel-induced neuropathic pain through 5-HT1A receptors without diminishing nervous system function or chemotherapy efficacy","volume":"171","author":"Ward","year":"2014","journal-title":"Br J Pharmacol"},{"key":"B21","doi-asserted-by":"publisher","first-page":"947","DOI":"10.1213\/ANE.0b013e3182283486","article-title":"Cannabidiol prevents the development of cold and mechanical allodynia in paclitaxel-treated female C57Bl6 mice","volume":"113","author":"Ward","year":"2011","journal-title":"Anesth Analg"},{"key":"B22","doi-asserted-by":"publisher","first-page":"2832","DOI":"10.1111\/bph.13887","article-title":"Single and combined effects of \u0394(9) -tetrahydrocannabinol and cannabidiol in a mouse model of chemotherapy-induced neuropathic pain","volume":"174","author":"King","year":"2017","journal-title":"Br J Pharmacol"},{"key":"B23","doi-asserted-by":"publisher","first-page":"4277","DOI":"10.3390\/ijms25084277","article-title":"Paclitaxel-associated mechanical sensitivity and neuroinflammation are sex-, time-, and site-specific and prevented through cannabigerol administration in C57Bl\/6 mice","volume":"25","author":"Li","year":"2024","journal-title":"Int J Mol Sci"},{"key":"B24","doi-asserted-by":"publisher","first-page":"1145","DOI":"10.3390\/biomedicines12061145","article-title":"Single and combined effects of cannabigerol (CBG) and cannabidiol (CBD) in mouse models of oxaliplatin-associated mechanical sensitivity, opioid antinociception, and naloxone-precipitated opioid withdrawal","volume":"12","author":"Hayduk","year":"2024","journal-title":"Biomedicines"},{"key":"B25","doi-asserted-by":"publisher","first-page":"1694","DOI":"10.1007\/s00125-020-05217-1","article-title":"Real-world evidence: the devil is in the detail","volume":"63","author":"Gokhale","year":"2020","journal-title":"Diabetologia"},{"key":"B26","doi-asserted-by":"publisher","first-page":"261","DOI":"10.1002\/pds.5407","article-title":"Core concepts in pharmacoepidemiology: confounding by indication and the role of active comparators","volume":"31","author":"Sendor","year":"2022","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"B27","doi-asserted-by":"publisher","first-page":"437","DOI":"10.1038\/nrrheum.2015.30","article-title":"Active-comparator design and new-user design in observational studies","volume":"11","author":"Yoshida","year":"2015","journal-title":"Nat Rev Rheumatol"},{"key":"B28","doi-asserted-by":"publisher","first-page":"2548","DOI":"10.3390\/biomedicines10102548","article-title":"Combinations of cannabidiol and \u0394(9)-tetrahydrocannabinol in reducing chemotherapeutic induced neuropathic pain","volume":"10","author":"Sepulveda","year":"2022","journal-title":"Biomedicines"},{"key":"B29","doi-asserted-by":"publisher","first-page":"1169","DOI":"10.1055\/s-0042-106303","article-title":"Effects of delta-9-tetrahydrocannabinol and cannabidiol on cisplatin-induced neuropathy in mice","volume":"82","author":"Harris","year":"2016","journal-title":"Planta Med"},{"key":"B30","doi-asserted-by":"publisher","first-page":"991","DOI":"10.3390\/life14080991","article-title":"Chemotherapy-induced peripheral neuropathy: a recent update on pathophysiology and treatment","volume":"14","author":"Mattar","year":"2024","journal-title":"Life (Basel)"},{"key":"B31","doi-asserted-by":"publisher","first-page":"5234943","DOI":"10.1155\/2018\/5234943","article-title":"Targeting the endocannabinoid system for prevention or treatment of chemotherapy-induced neuropathic pain: studies in animal models","volume":"2018","author":"Masocha","year":"2018","journal-title":"Pain Res Manag"},{"key":"B32","doi-asserted-by":"publisher","first-page":"479","DOI":"10.1016\/j.bpsc.2020.11.015","article-title":"Inhaled cannabis suppresses chemotherapy-induced neuropathic nociception by decoupling the raphe nucleus: a functional imaging study in rats","volume":"6","author":"Alkislar","year":"2021","journal-title":"Biol Psychiatry Cogn Neurosci Neuroimaging"},{"key":"B33","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1038\/s41572-023-00484-9","article-title":"Central neuropathic pain","volume":"9","author":"Rosner","year":"2023","journal-title":"Nat Rev Dis Primers"},{"key":"B34","doi-asserted-by":"publisher","first-page":"73","DOI":"10.1016\/j.neuron.2020.10.027","article-title":"Mechanical allodynia circuitry in the dorsal horn is defined by the nature of the injury","volume":"109","author":"Peirs","year":"2021","journal-title":"Neuron"},{"key":"B35","doi-asserted-by":"publisher","first-page":"797","DOI":"10.1016\/j.neuron.2015.07.029","article-title":"Dorsal horn circuits for persistent mechanical pain","volume":"87","author":"Peirs","year":"2015","journal-title":"Neuron"},{"key":"B36","doi-asserted-by":"publisher","first-page":"712","DOI":"10.1016\/j.jpain.2014.04.001","article-title":"Toll-like receptor 4 signaling contributes to paclitaxel-induced peripheral neuropathy","volume":"15","author":"Li","year":"2014","journal-title":"J Pain: Official journal of the American Pain Society"},{"key":"B37","doi-asserted-by":"publisher","first-page":"1025","DOI":"10.1093\/brain\/awad339","article-title":"Role of pattern recognition receptors in chemotherapy-induced neuropathic pain","volume":"147","author":"Araldi","year":"2024","journal-title":"Brain J Neurol"},{"key":"B38","doi-asserted-by":"publisher","first-page":"5856","DOI":"10.1073\/pnas.0501634102","article-title":"The CNS role of toll-like receptor 4 in innate neuroimmunity and painful neuropathy","volume":"102","author":"Tanga","year":"2005","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B39","doi-asserted-by":"publisher","first-page":"116671","DOI":"10.1016\/j.celrep.2025.116671","article-title":"Microglial macrophage-derived ds-HMGB1 in DRG orchestrates neuropathic pain through immune-neural signaling","volume":"44","author":"Yang","year":"2025","journal-title":"Cell Rep"},{"key":"B40","doi-asserted-by":"publisher","first-page":"5193","DOI":"10.1073\/pnas.1211204110","article-title":"Cannabinoid- and lysophosphatidylinositol-sensitive receptor GPR55 boosts neurotransmitter release at central synapses","volume":"110","author":"Sylantyev","year":"2013","journal-title":"Proc Natl Acad Sci U S A"},{"key":"B41","doi-asserted-by":"publisher","first-page":"e22246","DOI":"10.1002\/syn.22246","article-title":"Presynaptic nigral GPR55 receptors stimulate [(3) H]-GABA release through [(3) H]-cAMP production and PKA activation and promote motor behavior","volume":"76","author":"S\u00e1nchez-Zavaleta","year":"2022","journal-title":"Synapse (New York, N.Y.)"},{"key":"B42","doi-asserted-by":"publisher","first-page":"620525","DOI":"10.3389\/fnins.2021.620525","article-title":"PPAR \u03b3 prevents neuropathic pain by down-regulating CX3CR1 and attenuating M1 activation of microglia in the spinal cord of rats using a sciatic chronic constriction injury model","volume":"15","author":"Li","year":"2021","journal-title":"Front Neurosci"},{"key":"B43","doi-asserted-by":"publisher","first-page":"236","DOI":"10.1016\/j.neuropharm.2013.01.020","article-title":"PPAR\u03b3 activation blocks development and reduces established neuropathic pain in rats","volume":"70","author":"Morgenweck","year":"2013","journal-title":"Neuropharmacology"},{"key":"B44","doi-asserted-by":"publisher","first-page":"S23","DOI":"10.1097\/j.pain.0000000000000428","article-title":"The endocannabinoid system and neuropathic pain","volume":"157","author":"Maldonado","year":"2016","journal-title":"Pain"},{"key":"B45","doi-asserted-by":"publisher","first-page":"1956","DOI":"10.1111\/j.1476-5381.2011.01685.x","article-title":"Role of 5-HT(1) receptor subtypes in the modulation of pain and synaptic transmission in rat spinal superficial dorsal horn","volume":"165","author":"Jeong","year":"2012","journal-title":"Br J Pharmacol"},{"key":"B46","doi-asserted-by":"publisher","first-page":"399","DOI":"10.1097\/WNR.0b013e3283614cbf","article-title":"5-Hydroxytryptamine 1a receptors inhibit glutamate release in rat medullary dorsal horn neurons","volume":"24","author":"Choi","year":"2013","journal-title":"Neuroreport"},{"key":"B47","doi-asserted-by":"publisher","first-page":"137","DOI":"10.1016\/0304-3940(95)11397-F","article-title":"Alpha 2-adrenoceptor-mediated inhibition of capsaicin-evoked release of glutamate from rat spinal dorsal horn slices","volume":"188","author":"Ueda","year":"1995","journal-title":"Neurosci Lett"},{"key":"B48","doi-asserted-by":"publisher","first-page":"1938","DOI":"10.1152\/jn.00575.2001","article-title":"Inhibition of glutamatergic synaptic input to spinal lamina II(o) neurons by presynaptic alpha(2)-adrenergic receptors","volume":"87","author":"Pan","year":"2002","journal-title":"J Neurophysiol"},{"key":"B49","doi-asserted-by":"publisher","first-page":"682","DOI":"10.1097\/00000542-200303000-00016","article-title":"Alpha 2 adrenoceptor-mediated presynaptic inhibition of primary afferent glutamatergic transmission in rat substantia gelatinosa neurons","volume":"98","author":"Kawasaki","year":"2003","journal-title":"Anesthesiology"},{"key":"B50","doi-asserted-by":"publisher","first-page":"846","DOI":"10.3390\/biom11060846","article-title":"Y\u00e9venes, glycine receptors in spinal nociceptive control\u2014an update","volume":"11","author":"Zeilhofer","year":"2021","journal-title":"Biomolecules"},{"key":"B51","doi-asserted-by":"publisher","first-page":"2027","DOI":"10.1007\/s00018-005-5107-2","article-title":"The glycinergic control of spinal pain processing","volume":"62","author":"Zeilhofer","year":"2005","journal-title":"CMLS"},{"key":"B52","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.phrs.2016.12.019","article-title":"New approaches to target glycinergic neurotransmission for the treatment of chronic pain","volume":"116","author":"Imlach","year":"2017","journal-title":"Pharmacol Res"},{"key":"B53","doi-asserted-by":"publisher","first-page":"655","DOI":"10.1093\/jpp\/rgad023","article-title":"Cannabidiol prevents chemotherapy-induced neuropathic pain by modulating spinal TLR4 via endocannabinoid system activation","volume":"75","author":"Dos Santos","year":"2023","journal-title":"J Pharm Pharmacol"},{"key":"B54","doi-asserted-by":"publisher","first-page":"231","DOI":"10.1124\/jpet.124.002190","article-title":"KLS-13019, a novel structural analogue of cannabidiol and GPR55 receptor antagonist, prevents and reverses chemotherapy-induced peripheral neuropathy in rats","volume":"391","author":"Ippolito","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"B55","doi-asserted-by":"publisher","first-page":"105378","DOI":"10.1016\/j.jpain.2025.105378","article-title":"Cannabidiol reduces neuropathic pain and cognitive impairments through activation of spinal PPAR\u03b3","volume":"30","author":"Islas-Espinoza","year":"2025","journal-title":"J Pain: Official journal of the American Pain Society"},{"key":"B56","doi-asserted-by":"publisher","first-page":"434","DOI":"10.1007\/s13311-021-01164-w","article-title":"The cannabidiol analog PECS-101 prevents chemotherapy-induced neuropathic pain via PPAR\u03b3 receptors","volume":"19","author":"Silva","year":"2022","journal-title":"Neurotherapeutics"},{"key":"B57","doi-asserted-by":"publisher","first-page":"1121","DOI":"10.1084\/jem.20120242","article-title":"Cannabinoids suppress inflammatory and neuropathic pain by targeting \u03b13 glycine receptors","volume":"209","author":"Xiong","year":"2012","journal-title":"J Exp Med"},{"key":"B58","doi-asserted-by":"publisher","first-page":"110257","DOI":"10.1016\/j.neuropharm.2024.110257","article-title":"The cannabinoid CB(2) agonist LY2828360 suppresses neuropathic pain behavior and attenuates morphine tolerance and conditioned place preference in rats","volume":"265","author":"Guenther","year":"2025","journal-title":"Neuropharmacology"},{"key":"B59","doi-asserted-by":"publisher","first-page":"1958","DOI":"10.3390\/molecules29091958","article-title":"The potential antinociceptive effect and mechanism of cannabis sativa L. Extract on paclitaxel-induced neuropathic pain in rats uncovered by multi-omics analysis","volume":"29","author":"Xu","year":"2024","journal-title":"Molecules"},{"key":"B60","doi-asserted-by":"publisher","first-page":"214","DOI":"10.1124\/jpet.124.002212","article-title":"Select minor cannabinoids from cannabis sativa are cannabimimetic and antinociceptive in a mouse model of chronic neuropathic pain","volume":"391","author":"Schwarz","year":"2024","journal-title":"J Pharmacol Exp Ther"},{"key":"B61","doi-asserted-by":"publisher","first-page":"7461","DOI":"10.1007\/s00520-021-06321-7","article-title":"Diabetes mellitus as a risk factor for chemotherapy-induced peripheral neuropathy: a meta-analysis","volume":"29","author":"Gu","year":"2021","journal-title":"Support Care Cancer"},{"key":"B62","doi-asserted-by":"publisher","first-page":"2553","DOI":"10.1007\/s00520-019-05063-x","article-title":"Chemotherapy-induced peripheral neuropathy (CIPN) and its treatment: an NIH collaboratory study of claims data","volume":"28","author":"Gewandter","year":"2020","journal-title":"Support Care Cancer"},{"key":"B63","doi-asserted-by":"publisher","first-page":"93","DOI":"10.1016\/j.blre.2014.09.012","article-title":"The double-edged sword: neurotoxicity of chemotherapy","volume":"29","author":"Magge","year":"2015","journal-title":"Blood Rev"}],"container-title":["Frontiers in Pain Research"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1945720\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T05:40:44Z","timestamp":1790055644000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fpain.2026.1945720\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,22]]},"references-count":63,"alternative-id":["10.3389\/fpain.2026.1945720"],"URL":"https:\/\/doi.org\/10.3389\/fpain.2026.1945720","relation":{},"ISSN":["2673-561X"],"issn-type":[{"value":"2673-561X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,22]]},"article-number":"1945720"}}